Publications by authors named "Dora Ding"

Claim this Profile
A
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosis.
Jun Wang, Dora Ding, Xiaorong Shao, Lily Ma, Jun Xu

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
Elijah Weber, Islam R Younis, Cara Nelson, Dora Ding, Ann Qin

J Clin Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Rohit Loomba, Daniel Q Huang, Arun J Sanyal, Quentin Mark Anstee, Michael Trauner, Dora Ding

Gut· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Eric J Lawitz, Bal Raj Bhandari, Peter J Ruane, Anita Kohli, Eliza Harting, Dora Ding

Clin Gastroenterol Hepatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Arun J Sanyal, Quentin M Anstee, Michael Trauner, Eric J Lawitz, Manal F Abdelmalek, Dora Ding

Hepatology· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derivation and validation of the nonalcoholic fatty liver disease cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis.
Christian Labenz, Gerrit Toenges, Ming-Hua Zheng, Dora Ding, Robert P Myers

Eur J Intern Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit Loomba, Mazen Noureddin, Kris V Kowdley, Anita Kohli, Aasim Sheikh, Dora Ding

Hepatology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Andrew J Muir, Cynthia Levy, Harry L A Janssen, Aldo J Montano-Loza, Mitchell L Shiffman, Dora Ding

Hepatology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis